Business Wire

BIOIBÉRICA

9.3.2017 11:38:25 CET | Business Wire | Press release

Share
The Release of the First Documentary Dedicated to Heparin: a Centenary Drug That Saves over One Hundred Million Lives Each Year

“Everybody has heard of penicillin, but nobody knows what heparin is. And the fact is that heparin has saved as many lives as penicillin in the course of the 20 th century ”, explains Prof. Coen Hemker , a biochemist and Emeritus of the University of Maastricht, at the start of the documentary “Heparin: 100 years saving lives” . This 30-minute audiovisual recording has been directed by Carles Canet and produced by Broadcaster , with promotion from Bioibérica , to describe – on the basis of personal experiences – this anticoagulant drug which is so important in modern Medicine, having been declared a first-need drug by the World Health Organization.

In effect, this is the first documentary dedicated to this drug, and has been able to join the leading specialists and investigators in Hematology, Cardiology and Surgery, among other fields, as well as the drug industry, within one same audiovisual recording. Professionals from Spain (Hospital de la Santa Creu i Sant Pau , Hospital Universitari General de Catalunya , Hospital Germans Trias i Pujol , Banc de Sang i Teixits , Instituto Valenciano de Fertilidad , ISGlobal , IBEC ), the United States (Baylor University , Rensselaer Polytechnic Institute ), The Netherlands (Universidad de Maastricht , Synapse Research Institute ) and Italy (Instituto Ronzoni ), as well as international companies such as Sanofi , Laboratorios Rovi , BBraun or Bioibérica , have participated in the initiative

But the true central characters of this documentary are the patients who explain their own experiences: “I found it impossible to finish a training session and couldn’t believe that I would have to abandon water polo because of a clot in the subclavian vein at 17 years of age. Thanks to heparin, I was able to recover after six months, and everything that came afterwards was very much worthwhile”, explains Jennifer Pareja , a Spanish water polo player nominated the best player in the world in 2013.

The documentary can be seen online on Bioiberica website and is open to all those entities, educational institutions, organizations and people who wish to use and diffuse the recording. “Five out of every 10 people will need heparin at some point in life. Medicine wouldn’t be where it is today without it ”, explains Professor James Marcum , a historian at Baylor University in the United States.

Heparin , discovered in 1916, is a highly sulfated glycosaminoglycan – a natural substance composed of various molecules that inhibits blood clotting. Because of these properties, heparin is currently the most widely used drug for preventing and treating thrombosis. According to the International Society on Thrombosis and Hemostasis , one out of every four people in the world die of causes related to this disorder , which now produces more deaths each year than AIDS, breast cancer and traffic accidents combined.

Contact:

Bioibérica
Alba Soler i Conangla
+34 682 04 07 76 / +34 93 490 49 08
Communications Director
asoler@bioiberica.com
Visit our press room

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release

-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe

Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release

The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D

NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release

Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr

MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release

The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity

Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release

New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye